Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Other Accumulated Expenses (2020 - 2023)

Barinthus Biotherapeutics (BRNS) has disclosed Other Accumulated Expenses for 4 consecutive years, with $1.3 million as the latest value for Q3 2023.

  • For Q3 2023, Other Accumulated Expenses fell 50.17% year-over-year to $1.3 million; the TTM value through Sep 2023 reached $1.3 million, down 50.17%, while the annual FY2022 figure was $932000.0, 25.56% down from the prior year.
  • Other Accumulated Expenses hit $1.3 million in Q3 2023 for Barinthus Biotherapeutics, up from $638000.0 in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $2.6 million in Q3 2022 and bottomed at $46000.0 in Q2 2021.
  • Average Other Accumulated Expenses over 4 years is $922818.2, with a median of $932000.0 recorded in 2022.
  • Year-over-year, Other Accumulated Expenses skyrocketed 2091.3% in 2022 and then tumbled 50.17% in 2023.
  • Barinthus Biotherapeutics' Other Accumulated Expenses stood at $266000.0 in 2020, then soared by 370.68% to $1.3 million in 2021, then fell by 25.56% to $932000.0 in 2022, then soared by 41.09% to $1.3 million in 2023.
  • According to Business Quant data, Other Accumulated Expenses over the past three periods came in at $1.3 million, $638000.0, and $932000.0 for Q3 2023, Q2 2023, and Q4 2022 respectively.